GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma

NCT05668884 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

93

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Carcinoma

Interventions

COMBINATION_PRODUCT: Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab

Sponsor

Fudan University